Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Controlled, Adaptive Platform Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Vaccine Candidates Against Bundibugyo Virus Disease (BVD) in Contacts of Cases

NCT07842107 is registered in ClinicalTrials.gov with Jean-Pierre Van geertruyden as lead sponsor.

NCT NCT07842107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07842107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Controlled, Adaptive Platform Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Vaccine Candidates Against Bundibugyo Virus Disease (BVD) in Contacts of Cases
Lead sponsor
Jean-Pierre Van geertruyden
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 20, 2026
Completion date
June 30, 2027
Enrollment
3,620 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bundibugyo virus disease, ebola hemorrhagic fever